Shanghai Public Health Clinical Center Completed the First Patient Dosing

[Da2020]

https://finance.yahoo.com/news/shanghai-public-health-clinical-center-001000547.html

HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection, which was initiated by Shanghai Public Health Clinical Center, has completed the first patient dosing recently.

Previously, Ascletis announced the completion of the first patient dosing in the Phase II clinical trial of ASC22 as a monotherapy based on anti-retroviral therapy (ART) for immune restoration/ functional cure of human immunodeficiency virus 1 (HIV-1) infection

[nethan1621]

Well done china.. we need to end the monopoly of HIV business and increase more competitors in the field.. 😁😁 now we can analyze that  treating HIV is cheaper than Treating Diabetes with Insulin. India Biktarvy is just 40$ per month and other test are Free . Meanwhile another part of the world selling same drug for 5400$ .. what a scam.. business should be fair user policy guys.. we need more competitors … 🤓

[Jim Allen]

https://finance.yahoo.com/news/shanghai-public-health-clinical-center-001000547.html

HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection, which was initiated by Shanghai Public Health Clinical Center, has completed the first patient dosing recently.

Previously, Ascletis announced the completion of the first patient dosing in the Phase II clinical trial of ASC22 as a monotherapy based on anti-retroviral therapy (ART) for immune restoration/ functional cure of human immunodeficiency virus 1 (HIV-1) infection

Interesting read but a very early stage. Would like to see more data from them and have been unable to find anything peer reviewed yet.

[Jim Allen]

Well done china.. we need to end the monopoly of HIV business and increase more competitors in the field.. 😁😁 now we can analyze that  treating HIV is cheaper than Treating Diabetes with Insulin. India Biktarvy is just 40$ per month and other test are Free . Meanwhile another part of the world selling same drug for 5400$ .. what a scam.. business should be fair user policy guys.. we need more competitors … 🤓

Seems like they wanna stop unsafe activity based on previous published 99% effectiveness used to promote prep and now its time-to decrease unsafe activity after achieving considerable amount of prep users worldwide… pretty clear what they did.

Look stop it with this, half of this is plain rubbish and the other half seems to be an issue with capitalism, by all means, open a thread if you like on the topic of capitalism but stop responding to threads in the research section with this. 

[Da2020]

Interesting read but a very early stage. Would like to see more data from them and have been unable to find anything peer reviewed yet.

Me neither. Did a bunch of research still couldn’t find anything.( prolly a china thing)